Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology -- Ignore unavailable to you. Want to Upgrade?

To: bcjt who wrote (96)	5/2/2000 8:30:00 PM
From: bcjt	Read Replies (1) \| Respond to of 105

Maxxon Signs Safety Syringe Development Agreement With Genesis Design Group TULSA, Okla., May 2, 2000 (BW HealthWire) -- Maxxon, Inc. (OTCBB:MXON) announced today the execution of an exclusive Product Development Agreement with Genesis Design Group of Simi Valley, California, which provides for the design, engineering, computer modeling, verification and prototyping of Maxxon's new Safety Syringe. Maxxon recently acquired the exclusive worldwide rights to manufacture and market a novel proprietary safety syringe invented and developed by Mr. Wayland J. Rippstein, a retired NASA scientist. The syringe is a single-hand-operated, one-use vacuum safety syringe that retracts the contaminated needle into the barrel after use. The vacuum is created at the time of the injection and not at the time of manufacture, thus providing long shelf life. The Genesis Design Group is an industry leader in product development services with expertise in industrial design, engineering, analysis, 3D solid modeling and computer animation. The group expects to provide Maxxon with a prototype built to production specifications, complete with stereolithography parts for design verification, in 6-8 weeks. Mr Rippstein will be involved on behalf of Maxxon in all phases of the Genesis endeavor and will remain actively and directly involved with Genesis through the development of prototypes and commencement of manufacturing. Mr. Rippstein retired in 1983 from NASA as the Head of the Toxicology Laboratory, where he worked extensively with syringes, vacuums and other problems on the cutting edge of technology for more than 20 years. Since his retirement, Mr. Rippstein has been a consultant to various businesses. He has testified extensively as an expert witness in litigation involving the toxicological chemical effects of fires, explosions and other catastrophic events. Mr. Rippstein also owned and operated a chemical manufacturing firm for more than 7 years, selling primarily agricultural chemicals. He is a graduate of the University of Texas with a master's degree in Chemistry. Maxxon is a development stage company which has been refining a single-handed vacuum operated safety syringe for more than 2 years. Maxxon's objective is to help prevent accidental needlestick injuries and deaths to healthcare workers caused by unprotected, used needles. For more information, please contact: Morgan-Phillips, Inc. (800) 770-4856 (918) 250-8028 www.Morgan-Phillips.com This press release contains some forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in the Company's SEC filings. Distributed via COMTEX. Copyright (C) 2000 Business Wire. All rights reserved. -0- CONTACT: Morgan-Phillips, Inc. (800) 770-4856 (918) 250-8028 www.Morgan-Phillips.com bcjt